Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polycht With Cispatin and Gemcitabine and Fixed Dose Rate Infusion of Gem in Association With Cisplatin in 1st-line for Advanced NSCLC

NCT00385606 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT00385606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00385606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polycht With Cispatin and Gemcitabine and Fixed Dose Rate Infusion of Gem in Association With Cisplatin in 1st-line for Advanced NSCLC
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2003
Completion date
July 31, 2006
Enrollment
400 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer